Advertisement

Clinical and Translational Oncology

, Volume 14, Issue 6, pp 465–470 | Cite as

Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC

  • Xiao-Dong JiangEmail author
  • Yun Qiao
  • Peng Dai
  • Jin Wu
  • Da-An Song
  • Shi-Qiu Li
  • Yue-Wei Fan
Research Articles

Abstract

Objective

To investigate the clinical effects and adverse effects of weekly recombinant human endostatin (RHES) as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of non-small-cell lung cancer (NSCLC).

Methods

Fifty hypoxia-positive cases of pathology-diagnosed NSCLC (stage I–III) were randomly divided into a RHES+radiotherapy group (25 cases) and a radiotherapy alone group (25 cases). Intensity-modulated radiotherapy (IMRT) with a total dose of 60 Gy/30F/6W was adopted in the two groups. Target area included primary foci and metastatic lymph nodes. In the RHES+radiotherapy group, RHES (15 mg/day) was intravenously given during the first week. The therapeutic effects and adverse reactions were evaluated after treatment.

Results

In the RHES+radiotherapy and radiotherapy alone groups, the total effective rates (CR+PR) were 80% and 44% (χ2=6.87, p=0.009), respectively. The one-year and two-year local control rates were (78.9±8.4)% and (68.1±7.8)% (p=0.027), and (63.6±7.2)% and (43.4±5.7)% (p=0.022), respectively. The median progression-free survival was (21.1±0.97) and (16.5±0.95) months, respectively. The one-year and two-year overall survival rates were (83.3±7.2)% and (76.6±9.3)% (p=0.247), and (46.3±2.4)% and (37.6±9.1)% (p=0.218), respectively.

Conclusion

RHES combined with radiotherapy within the first week has better short-term therapeutic effects and local control rate, and no severe adverse reactions in treatment of NSCLC. However, it failed to significantly improve the one-year and two-year overall survival rates.

Keywords

Recombinant human endostatin Hypoxia Non-small-cell lung cancer Radiotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ling CH, Ji C, Chen YB et al (2004) Combined effects of endostatin gene transfer and ionizing radiation on lung adenocarcinoma model of A549 cells. Chin J Tuberc Respir Dis 27:683–686Google Scholar
  2. 2.
    Luo X, Andres ML, Timiryasova TM et al (2005) Radiation enhanced endostatin gene expression and effects of combination treatment. Technol Cancer Res Treat 4:193–202PubMedGoogle Scholar
  3. 3.
    Huang G, Chen L (2010) Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 136:1201–1211PubMedCrossRefGoogle Scholar
  4. 4.
    Carmeliet P, Jain PK (2000) Angiogenesis in cancer and other disease. Nature 407:249–257PubMedCrossRefGoogle Scholar
  5. 5.
    Dachs GU, Tozer GM (2000) Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 36:1649–1660PubMedCrossRefGoogle Scholar
  6. 6.
    Haugland HK, Vukovic V, Pintilie M et al (2002) Expression of hypoxia-inducible factor 1α in cervical carcinomas correlation with tumor oxygenation. Int J Radiation Oncol Biol Phys 53:854–861CrossRefGoogle Scholar
  7. 7.
    Jiang X-d, Dai P, Song D-a et al (2011) The correlation of 99mTc-HL91 hypoxia imaging and expression of HIF-1α. Modern Oncol 19:43–45Google Scholar
  8. 8.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  9. 9.
    Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation. Angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMedGoogle Scholar
  10. 10.
    Jiang X-d, Dai P, Wu J et al (2011) The inhibitory effects of radiotherapy combined with weekly dosage endostatin on the growth of transplanted human lung cancer cell line A549 in nude mice. Lung Cancer 72:165–171PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  • Xiao-Dong Jiang
    • 1
    • 2
    Email author
  • Yun Qiao
    • 1
  • Peng Dai
    • 1
  • Jin Wu
    • 1
  • Da-An Song
    • 1
  • Shi-Qiu Li
    • 1
  • Yue-Wei Fan
    • 1
  1. 1.Department of OncologyLianyungang First People’s HospitalLianyungangChina
  2. 2.Lianyungang CityJiangsu Province, China

Personalised recommendations